Takeda Pharmaceutical stock holds at EUR 16.55 before results
Published on 10/08/2026 at 09:53 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Takeda Pharmaceutical Company Limited (ISIN US8740602052) was trading at EUR 16.55 at Lang & Schwarz on October 8, 2026 at 9:39 a.m. CEST, unchanged versus the prior close of EUR 16.55 on October 7, 2026. Simply Wall St lists October 29, 2026 as Takeda's next earnings date.
Clinical data set the pipeline test
Takeda's most recent dated company release, issued September 30, 2026, centered on zasocitinib, an investigational oral treatment for moderate-to-severe plaque psoriasis. According to Takeda, 36.5 percent of patients receiving zasocitinib achieved complete skin clearance at week 16, compared with 13.9 percent in the deucravacitinib group.
The same release said 62.5 percent of zasocitinib patients achieved PASI 90 at week 16, versus 34.0 percent for deucravacitinib. The release also stated that zasocitinib remained under review by the U.S. Food and Drug Administration and the European Medicines Agency, keeping regulatory timing central to the pipeline case.
NYSE valuation adds a second reference
On the NYSE, TAK was last at USD 18.37 on October 7, 2026 at 4:00 p.m. ET. That level stood inside the USD 12.99 to USD 19.10 52-week range, leaving the stock USD 0.73 below the high based on the same currency and date.
Takeda's market capitalization was USD 58.5 billion as of October 7, 2026. The contrast between the unchanged European indication and the pipeline evidence gives the October 29 report a clear measurement point: revenue execution and the company's treatment pipeline will be assessed together.
Takeda stock awaits the next report
For investors tracking Takeda, the immediate reference is the EUR 16.55 Lang & Schwarz indication and the October 29 reporting date. The clinical comparison is material because zasocitinib's week-16 clearance rate was 22.6 percentage points above deucravacitinib in the cited Phase 3 study, while the candidate remains investigational.
The further course of trading is shown by the continuously updated real-time quote of Takeda Pharmaceutical stock.
Takeda Pharmaceutical stock at a glance
- Company: Takeda Pharmaceutical Company Limited
- ISIN: US8740602052
- Ticker: TAK
- Primary exchange: NYSE
- Price Lang & Schwarz (as of October 8, 2026, 9:39 a.m. CEST): EUR 16.55
- Prior close Lang & Schwarz (October 7, 2026): EUR 16.55
- Market capitalization: USD 58.5 billion (as of October 7, 2026)
- 52-week range: USD 12.99-19.10 (as of October 7, 2026)
- Sector / Industry: Healthcare / Drug Manufacturers - Specialty & Generic
- Next earnings date: October 29, 2026
